# Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome

> **NCT05933603** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Arizona** · enrollment: 36 (estimated)

## Conditions studied

- Obstructive Sleep Apnea
- Down Syndrome

## Interventions

- **DRUG:** Atomoxetine and Oxybutynin (ato-oxy)

## Key facts

- **NCT ID:** NCT05933603
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-29
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05933603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05933603, "Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05933603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*